Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases
Autor: | Ryo Tanaka, Yasutomo Nakai, Tomohiro Kanaki, Yohei Okuda, Kazuo Nishimura, Kenichi Kakimoto, Masashi Nakayama, Akira Nagahara, Yoshiyuki Yamamoto |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Radium-223 Oncology medicine.medical_specialty Multivariate analysis Bone Neoplasms 03 medical and health sciences Prostate cancer 0302 clinical medicine Surgical oncology Internal medicine Overall survival Humans Medicine Doubling time Aged Retrospective Studies business.industry Proportional hazards model Bone metastasis Hematology General Medicine Prognosis medicine.disease Prostatic Neoplasms Castration-Resistant 030104 developmental biology 030220 oncology & carcinogenesis Surgery business Radium medicine.drug |
Zdroj: | International Journal of Clinical Oncology. 26:192-198 |
ISSN: | 1437-7772 1341-9625 |
DOI: | 10.1007/s10147-020-01776-w |
Popis: | Radium-223 (Ra-223) is a targeted alpha therapy that has been shown to prolong overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. However, prognosis after Ra-223 administration varies among patients. The aim of the present study was to assess risk factors associated with the poor prognosis of patients treated with Ra-223. We retrospectively reviewed patients’ records of treatment with Ra-223 between October 2016 and December 2019. All patients had mCRPC, bone metastasis, and no known visceral metastases, and received up to six cycles of Ra-223 (55 kBq/kg). Prognostic factors for OS were analyzed by Cox proportional hazards model and log-rank test. We identified 42 patients who received at least one cycle of Ra-223 (median six cycles, range 1–6). Approximately two-thirds of patients had received at least two lines of therapy for mCRPC. The median age was 74 years, and the median follow-up duration was 13.6 months. The median OS time was 16.6 months. On multivariate analysis, PSA doubling time (PSADT) (0–3 months) at baseline, number of bone metastases (≥ 20), and treatment line of Ra-223 (4th–5th line) remained significantly correlated with the poor OS (HR 4.354, P = 0.003; HR 2.855, P = 0.020; and HR 4.871, P = 0.001, respectively). Our study demonstrated that a shorter PSADT, a heavier volume of bone metastases, and a later treatment line before Ra-223 are poor prognostic factors for mCRPC patients. These newly discovered risk factors may help select patients who potentially have long-term OS after Ra-223 treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |